AriBio Secures U.S. and Japan Patents for AR1001, Strengthening Commercialization Foundation

AriBio is expanding the global patent protection for AR1001, an oral candidate treatment for Alzheimer's disease, to strengthen the foundation for commercialization.

AriBio said on November 3 that it had completed the registration of a patent related to AR1001 in Japan and had received a notice of intent to grant a patent from the European Patent Office (EPO). After securing a U.S. patent last year, the company is extending its patent rights to major pharmaceutical markets, including Europe and Japan, as part of a strategy to strengthen its competitiveness in future global market entry and commercialization negotiations.

The patent, jointly filed by AriBio and SK Chemicals, is titled "Methods for Reducing Amyloid Beta Formation and Compositions Therefor." It protects the therapeutic use of mirodenafil and other treatments to reduce amyloid beta formation associated with Alzheimer's disease. Provided that the requirements for registration and maintenance are met, the patent is expected to remain in force through 2040.

With patent registration procedures advancing in Europe following the United States and Japan, the global intellectual property protection framework for AR1001's core technology has been further strengthened. The company said patent protection can serve as an important foundation not only for the product's future market entry but also for commercialization negotiations, including technology transfer.

AriBio is also pursuing additional patents and a product life cycle management strategy. The company plans to expand the scope of its intellectual property protection so that AR1001's development achievements continue to generate business value after commercialization.

Global Phase 3 results for AR1001 are also due to be released. On November 16, the company will present topline results from "POLARIS-AD," a global Phase 3 trial conducted in patients with early Alzheimer's disease, at the CTAD conference in Boston, United States.

Topline results contain key findings on a clinical trial's efficacy and safety, and are expected to serve as a key indicator of AR1001's potential as a new drug and its future commercial prospects.

A company official said, "Following the completion of the global Phase 3 trial, we are strengthening the foundation for AR1001's commercialization by expanding patent protection in major markets. The clinical trial results we will release this month will be an important milestone in evaluating AR1001's value as a new drug and gauging its potential for future global commercialization."

This content was produced with the assistance of AI translation services.